0001437749-19-006477.txt : 20190403 0001437749-19-006477.hdr.sgml : 20190403 20190403163035 ACCESSION NUMBER: 0001437749-19-006477 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190401 FILED AS OF DATE: 20190403 DATE AS OF CHANGE: 20190403 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wrighton-Smith Peter CENTRAL INDEX KEY: 0001592286 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36200 FILM NUMBER: 19729387 MAIL ADDRESS: STREET 1: C/O OXFORD IMMUNOTEC GLOBAL PLC STREET 2: 94C INNOVATION DRIVE CITY: ABINGDON STATE: X0 ZIP: OX14 4RZ ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Oxford Immunotec Global PLC CENTRAL INDEX KEY: 0001586049 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 94C INNOVATION DRIVE STREET 2: MILTON PARK CITY: ABINGDON STATE: X0 ZIP: OX14 4RZ BUSINESS PHONE: 44 01235 442780 MAIL ADDRESS: STREET 1: 94C INNOVATION DRIVE STREET 2: MILTON PARK CITY: ABINGDON STATE: X0 ZIP: OX14 4RZ 4 1 rdgdoc.xml FORM 4 X0306 4 2019-04-01 0001586049 Oxford Immunotec Global PLC OXFD 0001592286 Wrighton-Smith Peter C/O OXFORD IMMUNOTEC GLOBAL PLC 94C INNOVATION DRIVE ABINGDON, OXFORDSHIRE X0 OX14 4RZ UNITED KINGDOM 1 1 Chief Executive Officer Ordinary Shares 2019-04-01 4 A 0 31669 0 A 445138 D Ordinary Shares 2019-04-01 4 S 0 10000 16.6446 D 435138 D Ordinary Shares 2019-04-01 4 S 0 600 17.2096 D 434538 D Share Option (Right to Buy) 16.42 2019-04-01 4 A 0 67959 0 A 2029-04-01 Ordinary Shares 67959 67959 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2015, as amended. The price reported for the sales on April 1, 2019 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 to $17.25 per share, inclusive. The reporting person undertakes to provide Oxford Immunotec Global PLC, or any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. The price reported for the sales on April 1, 2019 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.20 to $17.25 per share, inclusive. The reporting person undertakes to provide Oxford Immunotec Global PLC, or any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4. Options granted under Issuer's 2013 Share Incentive Plan Options will become exercisable ratably on the anniversary of the vesting start date from January 1, 2020 through January 1, 2023. /s/ Elizabeth M. Keiley, as Attorney-in-Fact for Peter Wrighton-Smith 2019-04-03